Evidence map›Paper›PMID 40183219›Full record

ArticleImmunotherapy2025

Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.

Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai, Susan K Parsons

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Translational cancer research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao HuDivision of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.ORCID 0000-0001-9036-8455
Angie Mae RoddayInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Anastasia GurinovichInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Stacey PanDivision of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
Yana V SaleiDepartment of Medicine, Tufts Medical Center, Boston, MA, USA.
Jeffrey H LinDepartment of Medicine, Tufts Medical Center, Boston, MA, USA.
Margaret M ByrneDepartment of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Yu CaoDivision of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
Lori PaiDivision of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
Susan K ParsonsDivision of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.

Funding

Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
NCATS NIH HHS UL1 TR002544
6 · The paper itself

Abstract

backgroundImmune-checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment; however, immune-related adverse effects (irAEs) may occur. The risk factors of irAEs and the impact of irAEs on patient outcomes in LC remain uncertain. MATERIALS AND

methodsirAEs within 12 months of ICI initiation in LC patients who initiated ICIs 2018-2021 were identified. Cause-specific Cox regression was used to assess risk factors for irAEs with the competing risk of death; a subset analysis was done among non-small cell lung cancer (NSCLC) group. Multivariable Cox regressions were used to evaluate the impact of irAEs on progression-free survival (PFS) and overall survival (OS).

resultsOf 125 patients, 50 irAEs occurred in 39 patients. Small cell lung cancer (SCLC) histology was associated with a higher risk of irAEs (Hazard ratio (HR) = 2.73, 95% CI [1.17, 6.35],

conclusionSCLC histology and PDL1 positivity were associated with irAEs, and the occurrence of irAEs showed no impact on survival in LC patients. Future studies are required to validate the findings.

Indexed as

Carcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRisk FactorsImmune Checkpoint InhibitorsImmune-checkpoint inhibitorsimmune-related adverse eventslung canceroutcomesrisk factors

Identifiers

PMID40183219
PMCPMC12045565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.